Jasper Therapeutics (JSPR) Institutional Ownership → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free JSPR Stock Alerts $25.96 +1.86 (+7.72%) (As of 05/31/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Jasper Therapeutics (NASDAQ:JSPR)CurrentInstitutional OwnershipPercentage79.85%Number ofInstitutional Buyers(last 12 months)15TotalInstitutional Inflows(last 12 months)$60.24MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$744.99M Get JSPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Jasper Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data JSPR Institutional Buying and Selling by Quarter Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Jasper Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/29/2024 Opaleye Management Inc.435,573$12.79M2.8%-89.1%2.892% 5/20/2024 Virtu Financial LLC10,410$306K0.0%N/A0.069% 5/17/2024 Ikarian Capital LLC105,175$3.09M0.3%N/A0.698% 5/16/2024 Kingdon Capital Management L.L.C.497,000$14.59M1.6%-86.0%3.300% 5/14/2024 Qiming U.S. Ventures Management LLC928,964$27.27M30.4%-89.1%6.168% 5/14/2024 StemPoint Capital LP129,211$3.79M1.0%N/A0.858% Get the Latest News and Ratings for JSPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/10/2024 Vanguard Group Inc.612,745$17.99M0.0%-85.0%4.069% 5/8/2024 Russell Investments Group Ltd.79,811$2.34M0.0%N/A0.530% 5/7/2024 Concurrent Investment Advisors LLC20,409$599K0.0%N/A0.136% 5/3/2024 Carlyle Group Inc.1,066,189$31.30M2.0%-87.8%7.080% 3/18/2024 Kingdon Capital Management L.L.C.3,540,000$2.79M0.3%+16.4%31.720% 2/15/2024 Opaleye Management Inc.3,985,340$3.14M0.8%N/A35.717% 2/7/2024 Ieq Capital LLC54,500$43K0.0%N/A0.488% 2/7/2024 Monaco Asset Management SAM249,563$197K0.1%N/A2.236% 2/5/2024 Fernwood Investment Management LLC494,706$390K0.1%+8.8%4.433% 11/13/2023 Mariner LLC652,749$457K0.0%-8.7%0.589% 11/9/2023 Cowen AND Company LLC200,393$140K0.0%N/A0.181% 11/8/2023 Forefront Analytics LLC110,792$78K0.0%+59.7%0.100% 10/30/2023 Summit Trail Advisors LLC65,000$46K0.0%N/A0.059% 8/15/2023 Sphera Funds Management LTD.4,274,008$5.86M0.9%+5.7%3.874% 8/14/2023Jefferies Financial Group Inc.489,884$671K0.0%N/A0.444% 6/1/2023 Prelude Capital Management LLC54,500$99K0.0%N/A0.049% 5/16/2023 Ally Bridge Group NY LLC2,517,232$4.56M6.0%N/A2.301% 5/16/2023 BVF Inc. IL9,900,000$17.92M0.7%N/A9.051% 5/15/2023 Affinity Asset Advisors LLC476,948$863K0.3%N/A0.436% 5/15/2023 Kingdon Capital Management L.L.C.3,040,000$5.50M1.0%+463.0%2.779% 5/15/2023 RTW Investments LP2,329,809$4.22M0.1%N/A2.130% 5/12/2023 Forefront Analytics LLC30,290$55K0.0%-73.4%0.028% 5/5/2023 Carlyle Group Inc.8,761,891$15.77M0.5%N/A8.011% 5/3/2023 Jump Financial LLC33,074$60K0.0%N/A0.030% 4/25/2023 Qiming U.S. Ventures Management LLC8,519,648$15.42M18.7%+45.6%7.789% 2/13/2023 Forefront Analytics LLC114,000$55K0.0%-4.8%0.300% 2/7/2023 Fernwood Investment Management LLC454,706$220K0.1%+53.1%1.197% 11/14/2022 Forefront Analytics LLC119,800$94K0.1%+246.0%0.327% 11/9/2022 Fernwood Investment Management LLC297,080$234K0.1%N/A0.810% 5/10/2022 Sectoral Asset Management Inc.675,000$2.40M0.4%N/A1.782% 5/9/2022 Forefront Analytics LLC32,550$118K0.0%N/A0.086% 4/27/2022Vahanian & Associates Financial Planning Inc.10,000$36K0.1%-60.0%0.026% 2/15/2022 Kingdon Capital Management L.L.C.540,000$4.24M0.5%N/A1.427% 2/2/2022Grace Capital218,110$1.71M1.0%N/A0.576% This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry.1/28/2022Vahanian & Associates Financial Planning Inc.25,000$196K0.2%N/A0.066% 11/16/2021 Citadel Advisors LLC3,005,035$29.22M0.0%N/A8.228% 11/15/2021 Tudor Investment Corp Et Al20,000$205K0.0%N/A0.055% 11/15/2021Abingworth LLP5,628,558$58.03M13.2%N/A15.412% (Data available from 1/1/2016 forward) JSPR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of JSPR shares? During the previous two years, 25 institutional investors and hedge funds held shares of Jasper Therapeutics. The most heavily invested institutionals were Carlyle Group Inc. ($31.30M), Qiming U.S. Ventures Management LLC ($27.27M), Vanguard Group Inc. ($17.99M), BVF Inc. IL ($17.92M), Kingdon Capital Management L.L.C. ($14.59M), Opaleye Management Inc. ($12.79M), and Sphera Funds Management LTD. ($5.86M).Learn more on JSPR's institutional investors. What percentage of Jasper Therapeutics stock is owned by institutional investors? 79.85% of Jasper Therapeutics stock is owned by institutional investors. Learn more on JSPR's institutional investor holdings. Which institutional investors have been buying Jasper Therapeutics stock? Of the 23 institutional investors that purchased Jasper Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($9.90M), Carlyle Group Inc. ($8.76M), Opaleye Management Inc. ($3.99M), Kingdon Capital Management L.L.C. ($3M), Qiming U.S. Ventures Management LLC ($2.67M), Ally Bridge Group NY LLC ($2.52M), and RTW Investments LP ($2.33M). How much institutional buying is happening at Jasper Therapeutics? Institutional investors have bought a total of 35,981,122 shares in the last 24 months. This purchase volume represents approximately $593.27M in transactions. Which Jasper Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Jasper Therapeutics stock in the last 24 months: Carlyle Group Inc. ($7.70M), Qiming U.S. Ventures Management LLC ($7.59M), Opaleye Management Inc. ($3.55M), Vanguard Group Inc. ($3.48M), Kingdon Capital Management L.L.C. ($3.04M), Forefront Analytics LLC ($89.51K), and Mariner LLC ($62.25K). How much institutional selling is happening at Jasper Therapeutics? Institutional investors have sold a total of 25,511,123 shares in the last 24 months. This volume of shares sold represents approximately $746.53M in transactions. Related Companies: DocGo Major Shareholders Momentus Major Shareholders Vir Biotechnology Major Shareholders BioCryst Pharmaceuticals Major Shareholders Cullinan Therapeutics Major Shareholders Tarsus Pharmaceuticals Major Shareholders 4D Molecular Therapeutics Major Shareholders Ginkgo Bioworks Major Shareholders Humacyte Major Shareholders Autolus Therapeutics Major Shareholders This page (NASDAQ:JSPR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.